Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XRF ScientificASX:XRF -2.04%98 Debt-to-EBITDA is 0.14 as of Dec. 2025, which is 59% below its 10-year median of 0.34. GuruFocus rates ASX:XRF with a GF Score™ of 98/100 and a GF Value™ of A$1.66 (Fairly Valued). The stock has 1 warning sign investors should review. Among 460 Conglomerates companies, XRF Scientific ranks better than 95.22% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for XRF Scientific's Debt-to-EBITDA or its related term are showing as below:
ASX:XRF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.14 Med: 0.34 Max: 0.92
Current: 0.14
During the past 13 years, the highest Debt-to-EBITDA Ratio of XRF Scientific was 0.92. The lowest was 0.14. And the median was 0.34.
ASX:XRF's Debt-to-EBITDA is ranked better than 95.22% of 460
companies
in the Conglomerates industry
Industry Median: 2.755
vs ASX:XRF: 0.14
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
XRF Scientific Debt-to-EBITDA Related Terms
XRF Scientific Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for XRF Scientific's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Conglomerates subindustry, XRF Scientific's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XRF Scientific Debt-to-EBITDA vs Conglomerates Industry
For the Conglomerates industry and Industrials sector, XRF Scientific's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where XRF Scientific's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
XRF Scientific (ASX:XRF) has a Debt-to-EBITDA of 0.14 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on XRF Scientific. This is 59% below median its historical median of 0.34. Over the past decade, XRF Scientific's Debt-to-EBITDA has ranged from 0.14 to 0.92. According to the industry distribution chart, XRF Scientific ranks #22 out of 460 companies in the Conglomerates industry, placing it in the top 4.8%.
Is XRF Scientific's Debt-to-EBITDA too high?
XRF Scientific's current Debt-to-EBITDA of 0.14 is 59% below median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 0.92. The Conglomerates industry median Debt-to-EBITDA is 2.76. XRF Scientific's value of 0.14 is 94.9% below this industry median. Based on the distribution chart, XRF Scientific ranks #22 out of 460 companies in the Conglomerates industry, which is in the top quartile — a strong position relative to peers. Overall, XRF Scientific has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does XRF Scientific's Debt-to-EBITDA compare to HON and MMM?
According to the Conglomerates industry distribution chart, XRF Scientific ranks #22 out of 460 companies for Debt-to-EBITDA. This places XRF Scientific in the top 5% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.76. XRF Scientific's value of 0.14 is 94.9% below this benchmark. Historically, XRF Scientific's own Debt-to-EBITDA has ranged from 0.14 to 0.92 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 2.76, XRF Scientific has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Conglomerates company?
The median Debt-to-EBITDA among Conglomerates companies is 2.76, based on 460 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XRF Scientific's current Debt-to-EBITDA of 0.14 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on XRF Scientific. For the Conglomerates industry, the median Debt-to-EBITDA is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XRF Scientific's current Debt-to-EBITDA is 0.14, which is 59% below median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XRF Scientific stock overvalued right now?
Based on GuruFocus' analysis, XRF Scientific (ASX:XRF) is currently considered Fairly Valued. The stock's GF Value™ is A$1.66, compared to a current price of A$1.68 — trading 1.2% above its estimated fair value. The current Debt-to-EBITDA is 0.14, which is 59% below median its 10-year median of 0.34 and 94.9% below the Conglomerates industry median of 2.76. XRF Scientific's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For XRF Scientific (ASX:XRF), the current Debt-to-EBITDA is 0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is XRF Scientific (ASX:XRF) Overvalued in 2026?
Based on GuruFocus' analysis, XRF Scientific stock appears to be overvalued.
The current stock price of A$1.68 is trading 1.2% above its estimated GF Value™ of A$1.66.
GuruFocus considers XRF Scientific to be Fairly Valued.
Key valuation signals for ASX:XRF:
Debt-to-EBITDA: 0.14 (59% below median its 10-year median of 0.34)
GF Value™: A$1.66 vs. price of A$1.68 (1.2% above fair value)
Industry Position: 94.9% below the Conglomerates median (#22 of 460)
No single metric tells the full story. See the ASX:XRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
XRF Scientific Ltd is engaged in the business of manufacturing and marketing precious metal products, specialized chemicals and instruments for the scientific, analytical and mining industries. It operates through the following segments: Capital Equipment, Precious Metals, and Consumables. The company generates maximum revenue from the Capital Equipment segment that Manufactures sample preparation products and analytical instruments. Geographically, it derives a majority of revenue from Australia and also has a presence in Canada and Europe. Some of its product includes Electric Fusion Machines; Fusion Flux; Crushing and Pulverising, platinum lab ware and others.
98GF Score
Get the complete analysis for ASX:XRF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:XRF has been successfully added to your 
